These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

551 related articles for article (PubMed ID: 24361082)

  • 1. Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy.
    Vickery BP; Scurlock AM; Kulis M; Steele PH; Kamilaris J; Berglund JP; Burk C; Hiegel A; Carlisle S; Christie L; Perry TT; Pesek RD; Sheikh S; Virkud Y; Smith PB; Shamji MH; Durham SR; Jones SM; Burks AW
    J Allergy Clin Immunol; 2014 Feb; 133(2):468-75. PubMed ID: 24361082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early decrease in basophil sensitivity to Ara h 2 precedes sustained unresponsiveness after peanut oral immunotherapy.
    Patil SU; Steinbrecher J; Calatroni A; Smith N; Ma A; Ruiter B; Virkud Y; Schneider M; Shreffler WG
    J Allergy Clin Immunol; 2019 Nov; 144(5):1310-1319.e4. PubMed ID: 31377342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early oral immunotherapy in peanut-allergic preschool children is safe and highly effective.
    Vickery BP; Berglund JP; Burk CM; Fine JP; Kim EH; Kim JI; Keet CA; Kulis M; Orgel KG; Guo R; Steele PH; Virkud YV; Ye P; Wright BL; Wood RA; Burks AW
    J Allergy Clin Immunol; 2017 Jan; 139(1):173-181.e8. PubMed ID: 27522159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Administration of a probiotic with peanut oral immunotherapy: A randomized trial.
    Tang ML; Ponsonby AL; Orsini F; Tey D; Robinson M; Su EL; Licciardi P; Burks W; Donath S
    J Allergy Clin Immunol; 2015 Mar; 135(3):737-44.e8. PubMed ID: 25592987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring Ara h 1, 2 and 3-sIgE and sIgG4 antibodies in peanut allergic children receiving oral rush immunotherapy.
    Nozawa A; Okamoto Y; Movérare R; Borres MP; Kurihara K
    Pediatr Allergy Immunol; 2014 Jun; 25(4):323-8. PubMed ID: 24953293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IgE binding to linear epitopes of Ara h 2 in peanut allergic preschool children undergoing oral Immunotherapy.
    Dreskin SC; Germinaro M; Reinhold D; Chen X; Vickery BP; Kulis M; Burks AW; Negi SS; Braun W; Chambliss JM; Eglite S; McNulty CMG
    Pediatr Allergy Immunol; 2019 Dec; 30(8):817-823. PubMed ID: 31437325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Probiotic peanut oral immunotherapy versus oral immunotherapy and placebo in children with peanut allergy in Australia (PPOIT-003): a multicentre, randomised, phase 2b trial.
    Loke P; Orsini F; Lozinsky AC; Gold M; O'Sullivan MD; Quinn P; Lloyd M; Ashley SE; Pitkin S; Axelrad C; Metcalfe JR; Su EL; Tey D; Robinson MN; Allen KJ; Prescott SL; Galvin AD; Tang MLK;
    Lancet Child Adolesc Health; 2022 Mar; 6(3):171-184. PubMed ID: 35123664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allergen-specific oral immunotherapy for peanut allergy.
    Nurmatov U; Venderbosch I; Devereux G; Simons FE; Sheikh A
    Cochrane Database Syst Rev; 2012 Sep; 2012(9):CD009014. PubMed ID: 22972130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy.
    Narisety SD; Frischmeyer-Guerrerio PA; Keet CA; Gorelik M; Schroeder J; Hamilton RG; Wood RA
    J Allergy Clin Immunol; 2015 May; 135(5):1275-82.e1-6. PubMed ID: 25528358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutralizing IgG
    Keswani T; LaHood NA; Marini-Rapoport O; Karmakar B; Andrieux L; Reese B; Sneed SL; Pedersen LC; Mueller GA; Patil SU
    J Allergy Clin Immunol; 2024 Jun; 153(6):1611-1620.e7. PubMed ID: 38460677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of cytokine production by peanut-reactive T cells identifies residual Th2 effectors in highly allergic children who received peanut oral immunotherapy.
    Wisniewski JA; Commins SP; Agrawal R; Hulse KE; Yu MD; Cronin J; Heymann PW; Pomes A; Platts-Mills TA; Workman L; Woodfolk JA
    Clin Exp Allergy; 2015 Jul; 45(7):1201-13. PubMed ID: 25823600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blocking antibodies induced by peanut oral and sublingual immunotherapy suppress basophil activation and are associated with sustained unresponsiveness.
    Orgel K; Burk C; Smeekens J; Suber J; Hardy L; Guo R; Burks AW; Kulis M
    Clin Exp Allergy; 2019 Apr; 49(4):461-470. PubMed ID: 30383313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study.
    Chinthrajah RS; Purington N; Andorf S; Long A; O'Laughlin KL; Lyu SC; Manohar M; Boyd SD; Tibshirani R; Maecker H; Plaut M; Mukai K; Tsai M; Desai M; Galli SJ; Nadeau KC
    Lancet; 2019 Oct; 394(10207):1437-1449. PubMed ID: 31522849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained successful peanut oral immunotherapy associated with low basophil activation and peanut-specific IgE.
    Tsai M; Mukai K; Chinthrajah RS; Nadeau KC; Galli SJ
    J Allergy Clin Immunol; 2020 Mar; 145(3):885-896.e6. PubMed ID: 31805311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose oral immunotherapy for children with anaphylactic peanut allergy in Japan.
    Nagakura KI; Yanagida N; Sato S; Nishino M; Asaumi T; Ogura K; Ebisawa M
    Pediatr Allergy Immunol; 2018 Aug; 29(5):512-518. PubMed ID: 29603410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral Immunotherapy in Japanese Children with Anaphylactic Peanut Allergy.
    Nagakura KI; Sato S; Yanagida N; Nishino M; Asaumi T; Ogura K; Ebisawa M
    Int Arch Allergy Immunol; 2018; 175(3):181-188. PubMed ID: 29339650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response.
    Varshney P; Jones SM; Scurlock AM; Perry TT; Kemper A; Steele P; Hiegel A; Kamilaris J; Carlisle S; Yue X; Kulis M; Pons L; Vickery B; Burks AW
    J Allergy Clin Immunol; 2011 Mar; 127(3):654-60. PubMed ID: 21377034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical efficacy and immune regulation with peanut oral immunotherapy.
    Jones SM; Pons L; Roberts JL; Scurlock AM; Perry TT; Kulis M; Shreffler WG; Steele P; Henry KA; Adair M; Francis JM; Durham S; Vickery BP; Zhong X; Burks AW
    J Allergy Clin Immunol; 2009 Aug; 124(2):292-300, 300.e1-97. PubMed ID: 19577283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-resolution epitope mapping by AllerScan reveals relationships between IgE and IgG repertoires during peanut oral immunotherapy.
    Chen G; Shrock EL; Li MZ; Spergel JM; Nadeau KC; Pongracic JA; Umetsu DT; Rachid R; MacGinnitie AJ; Phipatanakul W; Schneider L; Oettgen HC; Elledge SJ
    Cell Rep Med; 2021 Oct; 2(10):100410. PubMed ID: 34755130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peanut oral immunotherapy results in increased antigen-induced regulatory T-cell function and hypomethylation of forkhead box protein 3 (FOXP3).
    Syed A; Garcia MA; Lyu SC; Bucayu R; Kohli A; Ishida S; Berglund JP; Tsai M; Maecker H; O'Riordan G; Galli SJ; Nadeau KC
    J Allergy Clin Immunol; 2014 Feb; 133(2):500-10. PubMed ID: 24636474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.